Une large étude confirme que les traitements hormonaux cutanés pour la ménopause n’augmentent pas le risque de thrombose

A landmark epidemiological study encompassing over one million women in Denmark has provided definitive reassurance regarding the cardiovascular safety of transdermal menopausal hormone therapies. Published in late October 2026, the comprehensive research reinforces a critical distinction in modern medicine: while oral hormone replacement therapies (HRT) continue to show a measurable elevation in the risk of blood clots—specifically venous thromboembolism—transdermal applications such as gels and patches remain entirely safe for cardiovascular health.

This major scientific validation arrives at a crucial time for public health discourse, particularly in countries like France, where lingering apprehension surrounding hormone therapy has drastically suppressed prescription rates. By clarifying the stark pharmacological differences between oral and cutaneous delivery methods, researchers hope to dismantle persistent stigmas that have historically deterred women from seeking effective relief from debilitating menopausal symptoms.

Understanding the Danish Cohort: Methodology and Scale

The scale of the Danish investigation makes its conclusions exceptionally robust. By tracking the health outcomes, medication histories, and cardiovascular events of over one million women over an extended observation period, epidemiologists were able to isolate the specific variables associated with different types of hormone delivery systems.

Venous thromboembolism (VTE)—commonly known as a blood clot—is a known complication linked to certain hormonal interventions, notably oral estrogens. When hormones are ingested orally, they must pass through the digestive system and the liver before entering the systemic circulation. This process, known as first-pass hepatic metabolism, stimulates the synthesis of clotting factors in the liver, thereby elevating the likelihood of thrombosis.

Conversely, transdermal treatments bypass the liver entirely. Absorbed directly through the skin via patches or gels, the hormones enter the bloodstream directly, maintaining therapeutic efficacy at significantly lower doses and avoiding the hepatic activation of coagulation proteins. The Danish study confirms that this physiological distinction translates directly into real-world clinical safety: women utilizing transdermal gels and patches exhibited no statistically significant increase in the risk of developing a thrombotic event compared to non-users.

The French Context: Low Adoption Rates and Public Skepticism

To understand the broader implications of these findings, one must examine the unique landscape of menopausal healthcare in France. According to data published in June 2026 by Epi-Phare—the joint scientific interest group established by the French National Agency for Medicines and Health Products Safety (ANSM) and the National Health Insurance (Assurance Maladie)—only 4.4% of women aged 45 to 60 were prescribed a menopausal hormone treatment in 2025.

This remarkably low utilization rate is the direct legacy of historical medical trauma. At the turn of the millennium, landmark international studies, most notably the Women’s Health Initiative (WHI) in the United States and the Million Women Study in the United Kingdom, highlighted potential long-term risks associated with hormone therapy. These included elevated risks of breast cancer, stroke, and cardiovascular disease.

However, these historical studies possessed a critical confounding factor: they predominantly evaluated oral synthetic hormones, which differ fundamentally from the standard protocols utilized in France and much of continental Europe. Despite the subsequent evolution of prescribing practices, the initial wave of alarming headlines left a lasting imprint on both public consciousness and medical practice, creating a climate of hesitation that persists today.

Deconstructing the Risks: Progesterone Types and Breast Cancer

The new Danish data aligns with a broader scientific consensus emphasizing that not all hormone therapies are pharmacologically identical. The safety profile of a given regimen depends heavily on the specific molecules utilized, particularly the progestogen component.

Historical studies that raised alarm bells often utilized synthetic progestins, such as medroxyprogesterone acetate, which were linked to an increased incidence of breast cancer. In contrast, the medical standard in France overwhelmingly favors safer alternatives: natural micronized progesterone or dydrogesterone. Extensive clinical data has consistently demonstrated that these bioidentical molecules do not carry the same carcinogenic risks as their synthetic counterparts when combined with transdermal estrogen.

Yet, despite these reassuring pharmacological profiles, the conflation of all hormone therapies into a single, high-risk category continues to deprive millions of women of relief from vasomotor symptoms such as hot flashes, night sweats, sleep disturbances, and genitourinary syndrome of menopause.

Timeline of Menopausal Hormone Therapy Research and Regulation

1. 2002-2003: The publication of the Women’s Health Initiative (WHI) trials and the British Million Women Study. These reports shake the medical world by associating oral hormone replacement therapy with increased risks of breast cancer and cardiovascular complications. Prescription rates plummet globally.
2. 2010s: European gynecological societies begin actively differentiating between oral and transdermal administration methods, noting that patches and gels do not trigger the same hepatic clotting pathways. Concurrently, French clinical guidelines increasingly standardize the use of transdermal estradiol combined with natural micronized progesterone.
3. June 2026: Epi-Phare releases a comprehensive pharmaco-epidemiological report revealing that only 4.4% of French women aged 45 to 60 utilize menopausal hormone treatments, underscoring a persistent cultural and medical reluctance.
4. October 2026: A sweeping Danish cohort study involving over one million women is published, definitively confirming that transdermal hormonal treatments do not elevate the risk of venous thromboembolism, providing powerful empirical backing for modern prescription practices.

Expert Analysis: Clinical Implications and Future Outlook

Medical professionals and endocrinologists view the confirmation from the Danish study as an essential educational milestone. For years, clinicians advocating for the safe use of menopausal therapies have faced an uphill battle against deeply entrenched fears.

"The medical community has long recognized the safety advantages of transdermal application, but translating this into patient confidence has been challenging," notes a prominent European specialist in women’s health. "When patients hear that hormone therapy carries risks, they rarely hear the vital nuance that those risks pertain to specific oral molecules and synthetic compounds. Studies of this magnitude give physicians the hard data needed to reassure patients."

Furthermore, as society increasingly recognizes menopause as a normal physiological transition that deserves proactive medical management, the destigmatization of safe therapeutic interventions becomes a public health imperative. Untreated menopausal symptoms not only diminish overall quality of life but can also impact long-term metabolic health, bone density, and cognitive well-being.

Conclusion: A Call for Informed, Personalized Medicine

The findings from the Danish cohort study reinforce a fundamental tenet of contemporary pharmacology: route of delivery and molecular structure matter profoundly. By proving definitively that transdermal menopausal hormone treatments do not increase the risk of thrombosis, the research offers a pathway forward for millions of women seeking safe symptom relief.

As health authorities continue to disseminate these findings, the medical community anticipates a gradual shift in clinical conversations. By moving past the generalized anxieties sparked by early 2000s research, patients and practitioners can embrace a nuanced, evidence-based approach to menopause—one that prioritizes individual comfort, long-term wellness, and absolute cardiovascular safety.